Lifordi Immunotherapeutics, Inc. presented first-in-human clinical data for LFD-200, a novel subcutaneously administered antibody-drug conjugate (ADC) that delivers a potent glucocorticoid directly to immune cells, at the EULAR 2026 congress in London. The Phase 1 study in healthy participants demonstrated that LFD-200 was well tolerated and exhibited dose-responsive anti-inflammatory activity without affecting serum cortisol levels, a key marker of systemic glucocorticoid toxicity. This finding is significant because current glucocorticoid therapies, while effective for inflammatory conditions like rheumatoid arthritis, are limited by systemic side effects such as adrenal suppression, osteoporosis, and increased infection risk. By targeting the drug directly to immune cells, LFD-200 aims to achieve local anti-inflammatory effects while minimizing systemic exposure.
The data, presented in a poster session, showed no impact on cortisol levels, suggesting that LFD-200 may avoid the adrenal suppression associated with conventional glucocorticoids. This safety profile could represent a major advancement for patients requiring long-term anti-inflammatory therapy. The company is currently dosing patients with moderate to severe rheumatoid arthritis in the Phase 1 study, with data expected by year-end 2026. If successful, LFD-200 could offer a new treatment option for autoimmune diseases that combines the potency of glucocorticoids with improved safety.
Lifordi is leveraging the success of ADCs, a technology more commonly used in oncology, to treat autoimmune and inflammatory disorders. The company's lead candidate, LFD-200, is designed to deliver a glucocorticoid payload specifically to activated immune cells, potentially reducing off-target effects. The Phase 1 results in healthy participants support further development in patients. For more information, visit www.lifordi.com and follow on LinkedIn.
The implications of these data are broad: if LFD-200 proves effective in rheumatoid arthritis, it could open the door to treating other glucocorticoid-responsive autoimmune diseases with a safer profile. The ability to administer the drug subcutaneously also offers convenience over intravenous infusions. Lifordi, backed by ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, is committed to changing how immune and inflammatory diseases are treated. The company is also applying its drug delivery platform to other payloads, including antisense oligonucleotides and siRNA, expanding its potential impact.
